Fulgent Genetics
FLGT
180 hedge funds and large institutions have $322M invested in Fulgent Genetics in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 62 reducing their positions, and 39 closing their positions.
2,012% more call options, than puts
Call options by funds: $47.2M | Put options by funds: $2.23M
0.56% more ownership
Funds ownership: 49.16% → 49.73% (+0.56%)
8% less funds holding
Funds holding: 196 → 180 (-16)
18% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 62
23% less capital invested
Capital invested by funds: $421M → $322M (-$98.9M)
36% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.67M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$7.57M |
| 3 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
+$5.16M |
| 4 |
BlackRock
New York
|
+$3.94M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$7.61M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$4.94M |
| 3 |
JP Morgan Chase
New York
|
-$4.39M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$2.87M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.54M |
FLGT Hedge Fund Activity: Q1 2024 in Review
180 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Fulgent Genetics (FLGT) for Q1 2024, worth a combined $322M — down 23% from $421M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of FLGT and 25 opened new positions — a net loss of 14 holders — while 62 trimmed existing stakes and 51 added.
The largest buyer was Millennium Management, adding an estimated $8.67M. The largest seller was Morgan Stanley, cutting an estimated $7.61M.
- 180 institutional investors held Fulgent Genetics (FLGT) as of Q1 2024, down from 196 in Q4 2023.
- Funds reported $322M of Fulgent Genetics stock for Q1 2024, down 23% quarter-over-quarter.
- 25 funds opened new Fulgent Genetics positions in Q1 2024 and 39 closed out, a net change of -14 holders.
- The largest Fulgent Genetics buyer in Q1 2024 was Millennium Management, an estimated $8.67M added.
- The largest Fulgent Genetics seller in Q1 2024 was Morgan Stanley, an estimated $7.61M sold.
Based on aggregated 13F filings for Q1 2024.